A wide-ranging agricultural bill that includes a provision to legalize hemp made its way through a crucial Senate committee on Wednesday, passing 20-1.
Last week, Senate Majority Leader Mitch McConnell (R-KY) inserted the cannabis provisions—which would remove hemp from the federal definition of marijuana and also free up hemp cultivators to receive federal crop insurance—into the 2018 Farm Bill. The move builds upon the senator’s successful effort to include protections for industrial hemp research programs against federal interference in the 2014 version of the bill.
.@SenateMajLdr has been an effective leader in our farming communities helping Kentucky to become a leader in hemp production. And with the passage of the Farm Bill, hemp will become legalized nationwide! https://t.co/hlYsE9kqgn
— Kentucky GOP (@KYGOP) June 12, 2018
“I think it’s time we took this step,” McConnell said before the Senate Committee on Agriculture, Nutrition and Forestry on Wednesday. “I think everybody has now figured it out that this is not the other plant,” he added, referring to hemp’s cannabis cousin, marijuana.
“All the people in rural Kentucky who grew up with tobacco are hoping that this will be really something. And as we all know, hemp is very diversified. It can end up in your car dashboard, it can end up in food, it can end up in certain kinds of pharmaceuticals. It’s time to figure it out and see where the market will take us. I think it’s an important new development in American agriculture.”
McConnell also appeared on the Senate floor earlier Wednesday to reaffirm his support for the bill’s hemp provision.
“It’s a landmark piece of legislation that will benefit farmers and communities throughout our country,” McConnell said. “I’m particularly excited that the legislation being considered today includes provisions from the Hemp Farming Act of 2018…which I introduced earlier this year.”
“This will empower farmers in Kentucky and other states to fully realize the potential of industrial hemp.”
Late on Tuesday, Sen. Chuck Grassley (R-IA) filed an amendment to the Farm Bill that would require the Justice Department to “modify the definition of the term ‘hemp’ and make a determination as to whether cannabidiol [CBD] should be a controlled substance” under federal law.
Hemp legalization advocates swiftly responded, urging committee members to oppose the proposed changes, which they feared would gut the intent of McConnell’s legislation.
Kentucky’s Commissioner of Agriculture also tweeted that “I STRONGLY oppose Senator Grassley’s Amendment.”
Kentucky's farmers and processors are making innovative CBD products available to consumers. We recorded millions of dollars in sales revenues last year. The Grassley Amendment must be STOPPED in its tracks. #KyAg365 (2/3)
— Commissioner Quarles (@KYAgCommish) June 13, 2018
Grassley spoke in defense of his proposed amendment, lamenting that he’d “objected on procedural grounds” to the hemp legalization provision and was ignored. He also argued that he’d support the legalization of industrial hemp, but not its derivatives such as CBD. Grassley voiced concerns that the bill would “allow any snake oil salesman” to peddle unregulated CBD products to patients suffering from conditions such as epilepsy and anxiety.
Grassley also claimed that the hemp legalization provision falls “squarely within the Judiciary Committee’s jurisdiction,” which he chairs, as opposed to the Senate Committee On Agriculture.
Notably, however, he didn’t call for a committee vote on his proposed amendment. Instead, he asked that members “work with me to modify this provision after this bill gets out of committee.”
McConnell pushed back against the senator’s remarks. He said that he felt confident in the integrity of the bill and the safeguards it provides after consulting with the Justice Department, the Food and Drug Administration (FDA) and the ranking member of the Senate Committee on the Judiciary. Grassley’s amendment would “undercut essential premise of the bill, namely that help and its derivatives should be a legal agricultural commodity,” McConnell said.
“Hemp should be allowed to flourish again in this county…”
During the Wednesday committee markup, several lawmakers voiced support for legalizing hemp, including Sens. Michael Bennet, (D-CO), Heidi Heitkamp (D-ND) and Amy Klobuchar (D-MN).
Though the bill could still be subject to further amendments when it reaches the Senate floor, it’s doubtful that the hemp provisions would face significant resistance given their sizable bipartisan support. McConnell is joined by Senate Minority Leader Chuck Schumer (D-NY) and Sen. Ron Wyden (D-OR), among others, who also favor of the provision.
McConnell also said he received assurances from U.S. Attorney General Jeff Sessions, a staunch marijuana prohibitionist, that while he wouldn’t embrace the hemp legalization move, he “is not going to oppose us,” the Associated Press reported.
I’d like to thank the Chairman & @SenStabenow for working w/ me to include my #HempFarmingAct in the bill. It builds on the success of the pilot program I championed in the 2014 farm bill by removing federal roadblocks to industrial hemp.
— Leader McConnell (@SenateMajLdr) June 13, 2018
Lawmakers argue that federal laws pertaining to hemp cultivation have done a disservice to farmers and businesses in the United States. While it’s legal to sell hemp products, such as clothing and cosmetics, it remains illegal to cultivate the non-psychoactive cousin of marijuana under federal law.
Wyden took to the Senate floor last week, accompanied by two baskets full of hemp products, to make just that point.
“There can’t be many policies on the books that are more anti-farmer than that one,” he said. “Hemp growers in places like Canada and China must just be laughing all the way to the bank. They’re cashing in, while our farmers have their hands tied by the current hemp restrictions.”
And in a statement provided to Marijuana Moment on Wednesday, Wyden said that [l]ifting the nonsensical ban on growing hemp in Oregon and nationwide reverses decades of policymaking that hurt farmers’ ability to innovate and grow jobs here at home.”
“Our bipartisan legislation will help farmers unlock the full economic potential of industrial hemp, spurring economic growth and creating good-paying red, white, and blue jobs in rural communities across the country. Passing the Hemp Farming Act through the Senate Agriculture Committee marks a huge step toward allowing consumers to buy products made with hemp grown in America.”
I’m thrilled the bipartisan #HempFarmingAct passed the #SenateAg committee today. This marks a huge step toward allowing consumers to buy products made in America with hemp grown in America. #FarmBill18 https://t.co/6I6np0Dei3
— Ron Wyden (@RonWyden) June 13, 2018
My bipartisan #HempFarmingAct w/ @SenateMajLdr, @SenJeffMerkley and @RandPaul will help farmers unlock the full economic potential of industrial hemp, spurring economic growth and creating good-paying red, white, and blue jobs in rural communities across the country.
— Ron Wyden (@RonWyden) June 13, 2018
“It’s a crock,” Schumer, the Democratic leader, said last month, of the nation’s ban on hemp. “It makes no sense that the [Drug Enforcement Administration] is the primary regulator, and that they stop farmers and investors from growing hemp. Why are we buying hemp from other countries, when we have hundreds of acres that could be grown right here in our backyard?”
In a related move, for the third year in a row, the Senate unanimously adopted a resolution last week that acknowledged “the growing economic potential of industrial hemp.” But with the 2018 Farm Bill, this could represent the first year that a hemp legalization provision actually passes in the Senate.
All of this hemp momentum comes as many lawmakers are vying for broader cannabis reform measures, including the newly filed STATES Act, which would exempt marijuana from the Controlled Substances Act for states where the plant has been legalized. It would also provide protections for banks dealing with legal cannabis businesses and legalize industrial hemp.
President Donald Trump told reporters that he “probably will end up supporting that [bill],” last week.
Attempts to include hemp-related amendments to the House version of the Farm Bill were blocked last month. That said, the Senate leader is in a good position to push the legislation forward through a bicameral conference committee, which will eventually craft a final bill to send to the president’s desk.
McConnell said a full Senate vote on the bill would take place before July 4.
See below for a summary of the Farm Bill’s hemp provisions, as prepared by the Agriculture Committee:
Sec. 7125 Supplemental and Alternative Crops; Hemp
x Reauthorizes a research project for supplemental and alternative crops including canola and hemp.
Sec. 7401 Critical Agricultural Materials Act
x Reauthorizes the Critical Agricultural Materials Act, and includes hemp as an eligible product.
Sec. 7415 Legitimacy of Industrial Hemp Research
x Requires the Secretary to conduct a study and report on the economic viability of the domestic production and sale of industrial hemp.
Sec. 10111 Hemp Production
x Amends the Agricultural Marketing Act of 1946 to allow states to regulate hemp growth and production, based on a state or tribal plan that includes information on locations of hemp production, testing for THC concentration, disposal of plants that are out of compliance, and negligence or other violations of the state or tribal plan.
x Requires states and tribes without USDA approved plans to follow federal laws and regulations promulgated by USDA on hemp production.
Sec. 10112 Rule of Construction
x Clarifies that nothing in this title authorizes interference with the interstate commerce of hemp.
Sec. 11101 Definitions
x Defines cover crop termination and defines hemp as used in section 297A of the Agricultural Marketing Act of 1946.
Sec. 11106 Insurance period
x Amends section 508(a)(2) of the Federal Crop Insurance Act by adding hemp.
Sec. 11112 Submission of policies and materials to board.
x Amends section 508(h) of the Federal Crop Insurance Act to allow the Corporation to waive the viability and marketability requirement in the case of a policy or pilot program relating to the production of hemp.
Sec. 11120 Agricultural commodity
x Amends section 518 of the Federal Crop Insurance Act by adding hemp.
Sec. 11121 Reimbursement of research, development, and maintenance costs
x Amends section 522(b) of the Federal Crop Insurance Act to allow the Board and Corporation to waive the viability and marketability requirements in the case of research and development relating to a policy to insure the production of hemp.
UPDATE June 13, 2018 8:38am PT: This story has been updated to include new comments from Sens. Grassley and McConnell.
Marijuana Policy Project Welcomes New Executive Director
The Marijuana Policy Project (MPP), the nation’s best-funded cannabis advocacy group, has named long-time social justice reform advocate Steve Hawkins as its next executive director.
Hawkins, who previously served as the executive director of the National Coalition to Abolish the Death Penalty (NCADP) and executive vice president of the NAACP, will assume responsibility for MPP’s national legalization advocacy efforts just months before a number of states vote to enact their own legal systems.
The decision was made after a “months-long candidate search that included several exceptionally qualified candidates,” MPP said in a press release.
“We are still battling the effects of decades of anti-marijuana legislation and propaganda in this country,” Hawkins told Marijuana Moment. “Huge strides have been made when it comes to setting the record straight, but our work is far from over and there is still a lot of misinformation out there that needs to be addressed.”
“Fundraising and maintaining momentum is also a core challenge for the movement, which is in some ways a victim of its own success. Thanks to the major gains it has made in recent years, many people think legalization is inevitable and that their donations are no longer needed or that they don’t need to take the time to write their elected officials. These laws are not going to change themselves and there is more need than ever for resources and engagement to support federal and state-level reform efforts.”
Hawkins’s experience running successful criminal justice reform campaigns—including a bipartisan effort to end capital punishment for juveniles during his time at the NCADP—made him an apt candidate to spearhead the fight to end prohibition, Troy Dayton, chair of MPP’s board of directors, said in a statement.
“Steve has a strong track record in the field of criminal justice reform, and he knows how to build a movement toward meaningful social change,” Dayton said. “We were not only impressed by his expertise and experience, but also his strong convictions regarding the injustice of marijuana prohibition.”
“The country is moving in the right direction on marijuana policy, but there is still a lot of work to be done.”
Hawkins also previously held leadership positions at Amnesty International and the Coalition for Public Safety.
He told Marijuana Moment that his three decades of experience “defending civil and human rights” has informed his belief that we should “bring an end to marijuana prohibition, which has had a hugely detrimental impact, especially to communities of color,” and that we should “replace it with a more sensible system of regulation.”
“I also believe it is critical we ensure those populations that were so negatively impacted by prohibition are able to participate in and experience the positive impacts of such a regulated system.”
At MPP, Hawkins will succeed Rob Kampia, who late last year left the organization he founded in 1995 to start a for-profit cannabis policy consulting firm called the Marijuana Leadership Campaign. Kampia’s departure was announced shortly after sexual misconduct allegations against him resurfaced amid the #MeToo movement.
Kampia offered some words of advice for the next person to occupy his former seat in a phone interview with Marijuana Moment:
“View yourself as a fundraiser who has to engage in transactional fundraising with the marijuana industry in part, and view yourself as needing to come up with a smart, strategic plan for lobbying in state legislatures rather than doing ballot initiatives where no one else is going to touch it. Do not view yourself as a spokesperson.”
Or in other words, less of a focus on talk, and more on action.
MPP named Matthew Schweich as the interim executive director while the group scouted for a replacement. Scweich will now serve as MPP’s deputy director overseeing marijuana reform initiatives in Michigan and Utah.
In a statement, MPP board member Joby Pritzker said Schweich “provided critical leadership during a challenging transition period for MPP.”
“He maintained the effectiveness of our advocacy operations, managed our fundraising efforts, and oversaw ballot initiative campaigns in multiple states, while at the same time leading our staff and assisting the board with the executive director search.”
The past few years have seen a number of leadership changeups at national pro-legalization groups.
NORML brought on Erik Altieri as executive director in 2016 after Allen St. Pierre left the organization following 11 years of service. And last year, the Drug Policy Alliance announced that it had hired Maria McFarland Sánchez-Moreno, who worked on international and domestic drug policies issues for 13 years at the Human Rights Watch, as the new executive director to replace retiring founder Ethan Nadelmann.
While the objective at all of these groups—promoting equitable drug policy reform in the United States—has remained the same, the nature of the movement has evolved. A majority of states have now legalized cannabis for medical or recreational purposes, and though state-level reform efforts continue, calls for change at the federal level are increasingly resonant.
That is to say, these new executive directors will face a different set of challenges than their predecessors did.
Photo courtesy of Beloit College.
UN Launches First-Ever Full Review Of Marijuana’s Status Under International Law
For the first time ever, the United Nations (UN) is launching an in-depth review of whether marijuana is properly classified under international drug treaties.
In a related development, the UN’s World Health Organization (WHO) has announced that cannabidiol (CBD), a compound in marijuana that is increasingly used for medical purposes, does not warrant being controlled under the global agreements.
“The Committee recommended that preparations considered to be pure CBD should not be scheduled within the International Drug Control Conventions,” WHO Director-General Tedros Adhanom Ghebreyesus wrote in a letter announcing the moves. “The Committee concluded that there is sufficient evidence to proceed to a Critical Review” of marijuana, hashish, cannabis extracts and THC.
That broader review is set for November, and follows the results of an initial pre-review conducted by WHO’s Expert Committee on Drug Dependence (ECDD) in June.
“A pre-review is the first step of the ECDD’s assessment process, where it is determined whether there is enough robust scientific information to proceed to the next step, called a critical review,” an explanatory document accompanying the new letter reads. “This initial evaluation is also an opportunity to identify gaps in the available scientific data. A critical review is carried out when there is sufficient scientific evidence to allow the ECDD to make informed an recommendation that the substance be placed under international control, or if its level of control should be changed.”
The reviews include analyses of the chemistry, pharmacology, toxicology, epidemiology and therapeutic use of the substances.
If the UN ultimately decides to change marijuana’s status under international law, it would trigger a review on U.S. scheduling, according to provisions of the Controlled Substances Act.
“Thankfully the World Health Organization has accepted the challenge of evaluating the placement of cannabis in the 1962 Single Convention treaty,” Michael Krawitz of Veterans for Medical Cannabis Access told Marijuana Moment. “Cannabis placement in the treaty was done in the absence of scientific evaluation and has provided the basis for a moral campaign against drugs by the USA for many decades. Since our work on medical access to cannabis has been based upon scientific inquiry we know that any rational assessment of the evidence leads the observer to understand cannabis indeed has proven medicinal value and, compared to other medicines, has profoundly fewer negative side effects.”
Here’s what the UN experts have determined so far:
“There are no case reports of abuse or dependence relating to the use of pure CBD. No public health problems have been associated with CBD use,” an annex attached to Ghebreyesus’s letter reads, noting that research has shown it to be effective in treating epilepsy. “CBD has been found to be generally well tolerated with a good safety profile.”
“Cannabidiol (CBD) is not specifically listed in the schedules of the 1961, 1971 or 1988 United Nations International Drug Control Conventions… There is no evidence that CBD as a substance is liable to similar abuse and similar ill-effects as substances in the 1961 or 1971 Conventions such as cannabis or THC, respectively. The Committee recommended that preparations considered to be pure CBD should not be scheduled.”
When it comes to whole-plant marijuana and resin, ECDD’s pre-review found that while “adverse effects” are possible and that cannabis can cause physical dependence, its current categorization in international treaties “may not appear to be consistent with the criteria.”
“Several countries permit the use of cannabis for the treatment of medical conditions such as back pain, sleep disorders, depression, post-injury pain, and multiple sclerosis,” the document says. “The evidence presented to the Committee did not indicate that cannabis plant and cannabis resin were liable to produce ill-effects similar to these other substances that are in Schedule IV of the 1961 Convention on Narcotic Drugs. The inclusion of cannabis and cannabis resin in Schedule IV may not appear to be consistent with the criteria for Schedule IV.”
“The Committee concluded that there is sufficient evidence to proceed to critical review of cannabis plant and cannabis resin at a future ECDD meeting and explore further the appropriateness of their current scheduling within the 1961 Convention.”
With respect to extracts and tinctures of cannabis, the committee similarly identified health issues associated with consumption, but said “there is limited evidence of a withdrawal syndrome upon abrupt cessation.”
The committee also looked at THC itself and isomers of THC, and recommended that both be subject to critical reviews in November.
Ghebreyesus’s letter is addressed to UN Secretary-General Antonio Guterres, who will be the ultimate recipient of WHO’s recommendations on cannabis and related extracts and compounds following the review.
Guterres was prime minister of Portugal when that nation decriminalized all drugs, a move he touted last year in an address to the UN’s Commission on Narcotic Drugs. After the critical reviews are in, that body will vote on whether to alter cannabis’s status under the international treaties.
Marijuana Moment Patreon supporters can see the full text of the new WHO letter on cannabis below:
North Dakota Marijuana Legalization Measure Qualifies For November Ballot
North Dakotans voted to approve medical cannabis two years ago, and now they will get the chance to decide on full marijuana legalization this November.
Activists collected a sufficient number of signatures to qualify a ballot measure that would allow adults over 21 to use and grow marijuana, the secretary of state’s office determined on Monday.
(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)
Photo courtesy of Philip Steffan.